AN2 Therapeutics, Inc. Shareholders' Equity
AN2 Therapeutics, Inc. (ANTX) had Shareholders' Equity of $75.92 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $75.92M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $81.76M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $53.06M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $60.38M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $75.92M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $81.76M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $53.06M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $60.38M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $68.84M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $73.33M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $81.85M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $87.67M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $98.35M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $110.60M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $124.70M 10-K · filed 2026-03-17 |
| 2023-09-30 | $138.97M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $87.76M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $82.52M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $95.37M 10-K · filed 2025-03-25 |
| 2022-09-30 | $105.57M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $115.86M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $115.41M 10-Q · filed 2023-11-09 |
| 2021-12-31 | -$47.41M 10-K · filed 2024-03-29 |
| 2021-09-30 | -$38.35M 10-Q · filed 2022-11-09 |
| 2021-06-30 | -$29.84M 10-Q · filed 2022-11-09 |
| 2021-03-31 | -$23.11M 10-Q · filed 2022-11-09 |
| 2020-12-31 | -$20.32M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |